Clicky

Takeda Pharmaceutical Company Limited(TAK) News

Date Title
Jul 21 Why Alkermes Tumbled On Its Positive Narcolepsy Study
Jul 21 Takeda Pharmaceutical Receives FDA 510(k) Clearance for Hyqvia Devices
Jul 21 Takeda Receives FDA 510(k) Clearance for HyHubTM and HyHubTM Duo Devices to Simplify HYQVIA® Administration
Jul 17 Keros Therapeutics Announces the First Patient Dosing in the Phase 3 RENEW Clinical Trial of Elritercept
Jul 15 Takeda Pharmaceutical (TAK) Gets GAMMAGARD LIQUID ERC Approved by FDA
Jul 14 The No. 1 Key To Wealth, According To Wahei Takeda, the ‘Warren Buffett of Japan’
Jul 14 Exchange-Traded Funds, Equity Futures Lower Pre-Bell Monday Amid Fresh Tariff Warnings
Jul 14 Takeda’s oral narcolepsy drug shines in two Phase III trials
Jul 14 Takeda to seek approval of new kind of narcolepsy drug after study data
Jul 14 Takeda Announces Positive Results from Two Pivotal Phase 3 Studies of Oveporexton (TAK-861) in Narcolepsy Type 1
Jul 2 What's Fueling Tempus AI's Explosive Sales Growth?
Jul 1 FDA approves Takeda’s Gammagard liquid ERC for primary immunodeficiency
Jun 30 Takeda Announces U.S. FDA Approval of GAMMAGARD LIQUID ERC, the Only Ready-to-Use Liquid Immunoglobulin Therapy with Low Immunoglobulin A (IgA) Content1
Jun 27 Tempus AI's Data Business Keeps Scaling Up: Can the Growth Pace Last?
Jun 27 Will Strong Asceniv Sales Drive ADMA Biologics Further?
Jun 25 Liver Organoid Breakthrough: Generating Organ-Specific Blood Vessels
Jun 25 Ocular Therapeutix (OCUL) Moves 8.6% Higher: Will This Strength Last?
Jun 25 ADMA vs Takeda: Which Plasma Therapy Stock Is the Better Buy Today?
Jun 24 Protagonist Therapeutics, Takeda Pharmaceutical Announce Positive Phase 3 Rusfertide Results for Polycythemia Vera
Jun 4 EC approves Takeda ADC plus chemo for stage IIb Hodgkin’s lymphoma